Frequent touchpoints assist each patient in understanding side effects and progress, and then tailor the next dose adjustment (or hold) accordingly
GLP 1 Drug Biosimilar Market Size, Share & Trends Analysis by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 GLP-1 biosimilars are biological medicines developed to be highly similar in quality, safety, and efficacy to the originator GLP-1 receptor agonists, such as semaglutide, liraglutide, and dulaglutide
Professional-only strength and purity standards
In the widely cited STEP 1 trial published in the New England Journal of Medicine , participants receiving Wegovy lost an average of 14.9% of their body weight after 68 weeks, compared to 2.4% weight loss in the placebo group
For a 70 mg vial, draw 3.0 mL
Gastrointestinal effects are the most frequently reported adverse reactions according to the SmPC, with specific frequencies from clinical trials including nausea (approximately 44%), diarrhoea (30%), vomiting (24%), and constipation (24%)
